JP2014508782A - ホルモン不応性乳癌の治療におけるｅｇｆｒファミリー受容体の阻害剤の使用 - Google Patents

ホルモン不応性乳癌の治療におけるｅｇｆｒファミリー受容体の阻害剤の使用 Download PDF

Info

Publication number
JP2014508782A
JP2014508782A JP2013557943A JP2013557943A JP2014508782A JP 2014508782 A JP2014508782 A JP 2014508782A JP 2013557943 A JP2013557943 A JP 2013557943A JP 2013557943 A JP2013557943 A JP 2013557943A JP 2014508782 A JP2014508782 A JP 2014508782A
Authority
JP
Japan
Prior art keywords
erbb3
antibody
inhibitor
patient
erbb2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013557943A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014508782A5 (enExample
Inventor
ガブリエラ ガルシア
ウィリアム クバセック
ビクター モヨ
ギャビン マックビース
Original Assignee
メリマック ファーマシューティカルズ インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メリマック ファーマシューティカルズ インコーポレーティッド filed Critical メリマック ファーマシューティカルズ インコーポレーティッド
Publication of JP2014508782A publication Critical patent/JP2014508782A/ja
Publication of JP2014508782A5 publication Critical patent/JP2014508782A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2013557943A 2011-03-11 2012-03-12 ホルモン不応性乳癌の治療におけるｅｇｆｒファミリー受容体の阻害剤の使用 Pending JP2014508782A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161451848P 2011-03-11 2011-03-11
US61/451,848 2011-03-11
US201261604281P 2012-02-28 2012-02-28
US61/604,281 2012-02-28
PCT/US2012/028792 WO2012125573A2 (en) 2011-03-11 2012-03-12 Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers

Publications (2)

Publication Number Publication Date
JP2014508782A true JP2014508782A (ja) 2014-04-10
JP2014508782A5 JP2014508782A5 (enExample) 2015-04-30

Family

ID=45894680

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013557943A Pending JP2014508782A (ja) 2011-03-11 2012-03-12 ホルモン不応性乳癌の治療におけるｅｇｆｒファミリー受容体の阻害剤の使用

Country Status (12)

Country Link
US (1) US20140134170A1 (enExample)
EP (1) EP2683741A2 (enExample)
JP (1) JP2014508782A (enExample)
KR (1) KR20140044796A (enExample)
CN (1) CN103562226A (enExample)
AU (1) AU2012229147B2 (enExample)
BR (1) BR112013022882A2 (enExample)
CA (1) CA2828075A1 (enExample)
EA (1) EA201300996A1 (enExample)
MX (1) MX2013010379A (enExample)
SG (1) SG192844A1 (enExample)
WO (1) WO2012125573A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019505555A (ja) * 2016-02-18 2019-02-28 ウニベルシタ デリィ ストゥディ ディ ジェノバ がん治療における抗エストロゲン剤有効性の増強のための擬絶食の使用
JP2019142969A (ja) * 2014-05-08 2019-08-29 シャンハイ インスティテュート オブ プランド パレントフッド リサーチ アノルドリン組成物および疾患を処置するための方法
JP2020520377A (ja) * 2017-05-17 2020-07-09 メルス ナムローゼ フェンノートシャップ 乳癌のためのＥｒｂＢ−２／ＥｒｂＢ−３二重特異性抗体と内分泌療法との組み合わせ
US11773170B2 (en) 2017-08-09 2023-10-03 Merus N.V. Antibodies that bind EGFR and cMET
US11780925B2 (en) 2017-03-31 2023-10-10 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
US11820825B2 (en) 2014-02-28 2023-11-21 Merus N.V. Methods of treating a subject having an EGFR-positive and/or ErbB-3-positive tumor
US12139548B2 (en) 2014-02-28 2024-11-12 Merus N.V. Antibody that binds ErbB-2 and ErbB-3

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ579644A (en) 2007-02-16 2012-05-25 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
US8895001B2 (en) * 2010-03-11 2014-11-25 Merrimack Pharmaceuticals, Inc. Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
HK1202431A1 (en) 2012-05-02 2015-10-02 Symphogen A/S Humanized pan-her antibody compositions
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
SG11201708491PA (en) 2015-04-17 2017-11-29 Merrimack Pharmaceuticals Inc Combination treatments with seribantumab
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017160990A1 (en) 2016-03-15 2017-09-21 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
CN110099680B (zh) 2016-10-11 2021-02-05 杜克大学 Er+乳腺癌的拉索昔芬治疗
CN115844877B (zh) * 2017-01-10 2024-07-23 浙江嘉驰医药开发有限公司 拉索昔芬调节膜结合雌激素信号的应用及治疗癌症的方法
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
CN117771239A (zh) 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗
TW202227504A (zh) * 2020-10-15 2022-07-16 大陸商上海翰森生物醫藥科技有限公司 抗ｅｒｂｂ３抗體或其抗原結合片段及其醫藥用途
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009500005A (ja) * 2005-06-15 2009-01-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 二重特異的単鎖Ｆｖ抗体分子およびその使用方法
WO2009126920A2 (en) * 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
WO2010059315A1 (en) * 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1997000271A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7390632B2 (en) 1999-09-30 2008-06-24 Tumor Biology Investment Group, Inc. Soluble ErbB3 receptor isoforms
US7638302B2 (en) 2001-05-31 2009-12-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 receptor isoforms
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
CA2480099C (en) 2002-03-26 2019-01-08 Zensun (Shanghai) Sci-Tech. Ltd. Erbb3 based methods and compositions for treating neoplasms
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
NZ579644A (en) * 2007-02-16 2012-05-25 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
BRPI0808551B1 (pt) 2007-03-01 2022-04-05 Symphogen A/S Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
AU2008250033A1 (en) 2007-05-11 2008-11-20 Enzon Pharmaceuticals, Inc. RNA antagonist compounds for the modulation of HER3
KR20110044905A (ko) 2008-08-15 2011-05-02 메리맥 파마슈티컬즈, 인크. 치료제에 대한 세포의 반응을 예측하는 방법 및 시스템
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
JP2012525432A (ja) 2009-04-29 2012-10-22 トレリス バイオサイエンス リミテッド ライアビリティー カンパニー ヘレグリン共役型ｈｅｒ３と免疫反応性の改善された抗体
JP2013507926A (ja) * 2009-10-14 2013-03-07 メリマック ファーマシューティカルズ インコーポレーティッド ＩＧＦ−１Ｒ及びＥｒｂＢ３シグナル伝達を標的とする二重特異的結合剤及びその使用
US8895001B2 (en) * 2010-03-11 2014-11-25 Merrimack Pharmaceuticals, Inc. Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
KR101764453B1 (ko) 2010-04-09 2017-08-02 아베오 파마슈티컬즈, 인크. 항-erbb3 항체
JP2013539453A (ja) * 2010-07-09 2013-10-24 エクセリクシス， インク． 癌の治療のためのキナーゼ阻害物質の組み合わせ

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009500005A (ja) * 2005-06-15 2009-01-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 二重特異的単鎖Ｆｖ抗体分子およびその使用方法
WO2009126920A2 (en) * 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
WO2010059315A1 (en) * 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN5014005170; ＮＩＥ　ＬＩＮ: 'ＥＦＦＩＣＡＣＹ　ＯＦ　ＭＭ１２１　ＩＮ　ＥＲ＋　ＡＮＤ　ＴＲＩＰＬＥ　ＮＥＧＡＴＩＶＥ　ＢＲＥＡＳＴ　ＣＡＮＣＥＲ　ＳＴＵＤＩＥＳ' ＰＲＯＣＥＥＤＩＮＧＳ　ＯＦ　ＴＨＥ　ＡＮＮＵＡＬ　ＭＥＥＴＩＮＧ　ＯＦ　ＴＨＥ　ＡＭＥＲＩＣＡＮ　ＡＳＳＯＣＩＡＴＩＯＮ　ＦＯＲ　ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ Ｖ５１, 20100417, Ｐ４３６, ＡＭＥＲＩＣＡＮ　ＡＳＳＯＣＩＡＴＩＯＮ　ＦＯＲ　ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ *
JPN6015051314; ＰＲＡＲ，Ａ．　ａｎｄ　ＢＡＳＥＬＧＡ，　Ｊ．: Ｎａｔ　Ｃｌｉｎ　Ｐｒａｃｔ　Ｏｎｃｏｌ Ｖｏｌ．５，　Ｎｏ．９, 2008, ｐ．５３１-４２ *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11820825B2 (en) 2014-02-28 2023-11-21 Merus N.V. Methods of treating a subject having an EGFR-positive and/or ErbB-3-positive tumor
US12139548B2 (en) 2014-02-28 2024-11-12 Merus N.V. Antibody that binds ErbB-2 and ErbB-3
US10857158B2 (en) 2014-05-08 2020-12-08 Zhejiang Jiachi Development Pharmaceuticals Ltd Anordrin compositions and methods for treating diseases
US11911397B2 (en) 2014-05-08 2024-02-27 Zhejiang Jiachi Development Pharmaceuticals Ltd Anordrin compositions and methods for treating diseases
JP2019142969A (ja) * 2014-05-08 2019-08-29 シャンハイ インスティテュート オブ プランド パレントフッド リサーチ アノルドリン組成物および疾患を処置するための方法
JP2019505555A (ja) * 2016-02-18 2019-02-28 ウニベルシタ デリィ ストゥディ ディ ジェノバ がん治療における抗エストロゲン剤有効性の増強のための擬絶食の使用
JP7071272B2 (ja) 2016-02-18 2022-05-18 ウニベルシタ デリィ ストゥディ ディ ジェノバ がん治療における抗エストロゲン剤有効性の増強のための擬絶食の使用
US11780925B2 (en) 2017-03-31 2023-10-10 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
US12247078B2 (en) 2017-03-31 2025-03-11 Merus N.V. ERBB-2 and ERBB-3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
JP2023085422A (ja) * 2017-05-17 2023-06-20 メルス ナムローゼ フェンノートシャップ 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
JP7296891B2 (ja) 2017-05-17 2023-06-23 メルス ナムローゼ フェンノートシャップ 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
JP2020520377A (ja) * 2017-05-17 2020-07-09 メルス ナムローゼ フェンノートシャップ 乳癌のためのＥｒｂＢ−２／ＥｒｂＢ−３二重特異性抗体と内分泌療法との組み合わせ
US12195551B2 (en) 2017-05-17 2025-01-14 Merus N.V. Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
US11773170B2 (en) 2017-08-09 2023-10-03 Merus N.V. Antibodies that bind EGFR and cMET
US12668638B2 (en) 2017-08-09 2026-06-30 Merus B.V. Antibodies that bind EGFR and cMET

Also Published As

Publication number Publication date
EA201300996A1 (ru) 2014-01-30
WO2012125573A2 (en) 2012-09-20
WO2012125573A3 (en) 2012-12-27
CN103562226A (zh) 2014-02-05
EP2683741A2 (en) 2014-01-15
CA2828075A1 (en) 2012-09-20
US20140134170A1 (en) 2014-05-15
AU2012229147A1 (en) 2013-03-14
MX2013010379A (es) 2014-03-27
BR112013022882A2 (pt) 2016-12-20
NZ614427A (en) 2015-08-28
KR20140044796A (ko) 2014-04-15
AU2012229147B2 (en) 2015-12-24
SG192844A1 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
JP6185102B2 (ja) トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用
AU2012229147B2 (en) Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers
KR20140023921A (ko) ＥｒｂＢ 경로 저해제들에 대한 저항성을 극복하는 방법
CN110036030A (zh) 癌症的组合疗法
US20240317884A1 (en) Method for allowing immune cells infiltration in tumors
JP2014527035A (ja) 婦人科悪性腫瘍を治療するためのパクリタキセルとの組み合わせの抗ＥｒｂＢ３抗体
WO2022223006A1 (zh) 抗pd-1抗体联合一线化疗治疗晚期非小细胞肺癌的用途
JP2020520377A (ja) 乳癌のためのＥｒｂＢ−２／ＥｒｂＢ−３二重特異性抗体と内分泌療法との組み合わせ
NZ614427B2 (en) Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
HK1174254B (en) Use of erbb3 inhibitors in the treatment of triple negative breast cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150310

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160523